Want to see TSE:XRTX full AI Analyst Report?
XRTX Stock Chart & Stats
C$2.95
-C$0.11(-3.73%)
At close: 4:00 PM EDT
C$2.95
-C$0.11(-3.73%)
Day’s Range― - ―
52-Week RangeC$2.43 - C$9.85
Previous CloseN/A
Volume6.91K
Average Volume (3M)11.08K
Market Cap
C$5.18M
Enterprise ValueC$3.77
Total Cash (Recent Filing)C$992.43K
Total Debt (Recent Filing)C$0.00
Price to Earnings (P/E)―
Beta0.21
Next Earnings
Nov 12, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-7.21
Shares Outstanding1,816,565
10 Day Avg. Volume30,736
30 Day Avg. Volume11,079
Financial Highlights & Ratios
PEG Ratio0.03
Price to Book (P/B)1.75
Price to Sales (P/S)0.00
P/FCF Ratio-1.29
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-1.75
Revenue Forecast (FY)C$3.25M
Bulls Say, Bears Say
Bulls Say
Low LeverageMinimal debt limits interest and refinancing pressure, preserving financial flexibility while the company funds clinical development. This is a durable balance-sheet advantage, although it does not offset the need for operating and development capital.
Focused Therapeutic PipelineA focused pipeline targeting kidney and metabolic disorders can concentrate research resources and clinical expertise on defined unmet needs. Success in these indications could create a coherent platform, though commercial and clinical validation remain outstanding.
Clinical Development PlatformConcentration on related uric-acid and renal-disease mechanisms may allow knowledge and development capabilities to transfer across indications. This platform orientation could support multiple opportunities if lead programs demonstrate efficacy and safety.
Bears Say
No Product RevenueWithout product, licensing, or royalty revenue, the company has no operating sales base to fund research, trials, or corporate costs. Financial progress therefore depends on clinical milestones and future financing until a therapy reaches commercialization.
Persistent Losses And Cash BurnRecurring losses and negative operating and free cash flow show that the business is not self-funding. Continued development spending will likely require additional capital, creating a durable risk to financial flexibility until clinical programs mature.
External Funding And Dilution RiskDependence on equity financing exposes shareholders to dilution and financing availability risk. Material equity fluctuations also indicate that the balance sheet is driven largely by capital raises rather than retained operating earnings or recurring cash generation.
XORTX Therapeutics Inc News
XRTX FAQ
What was XORTX Therapeutics Inc’s price range in the past 12 months?
XORTX Therapeutics Inc lowest stock price was C$2.42 and its highest was C$9.85 in the past 12 months.
What is XORTX Therapeutics Inc’s market cap?
XORTX Therapeutics Inc’s market cap is C$5.18M.
When is XORTX Therapeutics Inc’s upcoming earnings report date?
XORTX Therapeutics Inc’s upcoming earnings report date is Nov 12, 2026 which is in 82 days.
How were XORTX Therapeutics Inc’s earnings last quarter?
XORTX Therapeutics Inc released its earnings results on Aug 15, 2026. The company reported -C$1.446 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is XORTX Therapeutics Inc overvalued?
According to Wall Street analysts XORTX Therapeutics Inc’s price is currently Overvalued.
Does XORTX Therapeutics Inc pay dividends?
XORTX Therapeutics Inc does not currently pay dividends.
What is XORTX Therapeutics Inc’s EPS estimate?
XORTX Therapeutics Inc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does XORTX Therapeutics Inc have?
XORTX Therapeutics Inc has 1,816,565 shares outstanding.
What happened to XORTX Therapeutics Inc’s price movement after its last earnings report?
XORTX Therapeutics Inc reported an EPS of -C$1.446 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -20.288%.
Which hedge fund is a major shareholder of XORTX Therapeutics Inc?
Currently, no hedge funds are holding shares in TSE:XRTX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
XORTX Therapeutics Inc
Based in Vancouver, Canada, XORTX Therapeutics Inc. is a biopharmaceutical firm dedicated to discovering and bringing to market treatments for a variety of conditions, including progressive kidney disorders, diabetes, insulin resistance, metabolic syndrome, and infections. The company's pipeline includes XRx-008, a late-stage clinical program addressing autosomal dominant polycystic kidney disease; XRx-101, an agent designed to reduce uric acid levels in COVID-19 patients to prevent acute kidney injury and its associated health issues; and XRx-221, a series of xanthine oxidase inhibitor candidates aimed at treating diabetic nephropathy. Furthermore, XORTX Therapeutics collaborates with the Icahn School of Medicine to research the occurrence of acute kidney injury and elevated uric acid in patients hospitalized with COVID-19.